Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats

Simple item page
dc.contributor.authorTulek, Baykal
dc.contributor.authorKiyan, Esen
dc.contributor.authorKiyici, Aysel
dc.contributor.authorToy, Hatice
dc.contributor.authorBariskaner, Hulagu
dc.contributor.authorSuerdem, Mecit
dc.date.accessioned2020-03-26T18:25:20Z
dc.date.available2020-03-26T18:25:20Z
dc.date.issued2012
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractStatins reduce cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase and have a major place in the treatment of atherosclerotic disease. Recent studies have shown anti-inflammatory properties of statins. The purpose of this study was to evaluate the anti-inflammatory effect of simvastatin on bleomycin (BLM)-induced pulmonary fibrosis in rats. A total of 31 female Sprague-Dawley rats were divided into four groups: (1) intratracheal (IT) phosphate-buffered saline (PBS) + intraperitoneal (IP) PBS (n=7); (2) IT BLM + IP PBS (n=8); (3) IT BLM + low dose (LD) simvastatin (1 mg/kg daily, n=8); (4) IT BLM + high dose (HD) simvastatin (5 mg/kg daily, n=8). Simvastatin was administered IP for 15 days, beginning 1 day prior to IT BLM. The effect of simvastatin on pulmonary fibrosis was studied by measurements of IL-13, PDGF, IFN-gamma, TGF-beta 1 levels in bronchoalveolar lavage (BAL) fluid and lung tissue hydroxyproline (HPL) content and by histopathological examination (Ashcroft score). BLM caused significant change in BAL fluid cytokine levels and increased both HPL content and histopathological score (p<0.001 for all). While LD simvastatin had no effect on cytokine levels, HD significantly reduced IL-13 (15.12 +/- 7.08 pg /ml vs. 4.43 +/- 2.34 pg/mL; p<0.05) and TGF-beta 1 levels (269.25 +/- 65.42 pg/mL vs. 131.75 +/- 32.65 pg/mL; p<0.05). Neither HD nor LD simvastatin attenuated HPL content or Ashcroft score. In conclusion, this study showed that LD simvastatin had no effect on a BLM-induced pulmonary fibrosis model, while the high dose caused partial improvement in profibrotic cytolcine levels.en_US
dc.identifier.doi10.4067/S0716-97602012000400003en_US
dc.identifier.endpage350en_US
dc.identifier.issn0716-9760en_US
dc.identifier.issn0717-6287en_US
dc.identifier.issue4en_US
dc.identifier.pmid23558989en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage345en_US
dc.identifier.urihttps://dx.doi.org/10.4067/S0716-97602012000400003
dc.identifier.urihttps://hdl.handle.net/20.500.12395/27992
dc.identifier.volume45en_US
dc.identifier.wosWOS:000314144500003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSOC BIOLGIA CHILEen_US
dc.relation.ispartofBIOLOGICAL RESEARCHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleEffects of simvastatin on bleomycin-induced pulmonary fibrosis in female ratsen_US
dc.typeArticleen_US

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu